MOLECULAR AND CELLULAR NEUROSCIENCE, published by Academic Press Inc Elsevier Science, is a pivotal journal dedicated to the expansive fields of Cellular and Molecular Neuroscience, providing a platform for the dissemination of innovative research and theoretical advancements since its establishment in 1990. With an ISSN of 1044-7431 and a commitment to high scholarly standards, this journal holds a notable Q2 ranking in key categories such as Cell Biology and Molecular Biology, highlighting its significant impact within the academic community. Although currently not an Open Access journal, it offers a wealth of insightful contributions aimed at fostering understanding and collaboration among researchers, professionals, and students. The journal's ongoing publication trajectory through to 2024 guarantees a continuous flow of cutting-edge research that is critical for addressing complex questions in neuroscience. As it plays a crucial role in advancing our understanding of molecular mechanisms underpinning neural function and pathology, MOLECULAR AND CELLULAR NEUROSCIENCE remains an essential reference for anyone invested in these dynamic fields.

CELLULAR AND MOLECULAR NEUROBIOLOGY, published by SPRINGER/PLENUM PUBLISHERS, stands as a significant contributor to the fields of cell biology and neuroscience, holding a distinguished position in the academic community with an impact factor that places it in the Q2 category for both Cell Biology and Cellular and Molecular Neuroscience, along with Q1 in Medicine (miscellaneous). Since its inception in 1981, this journal has provided a critical platform for innovative research and thought-provoking reviews, fostering a deeper understanding of complex neurobiological mechanisms. The journal’s rigorous peer-review process ensures the publication of high-quality manuscripts that offer valuable insights into cellular processes and neural functions. With a commitment to advancing knowledge and promoting collaboration among researchers, CELLULAR AND MOLECULAR NEUROBIOLOGY remains an essential resource for professionals and students alike, looking to stay updated on the latest developments in neurobiology.

NATURE NEUROSCIENCE is a premier journal published by NATURE PORTFOLIO, focusing on cutting-edge research in the field of neuroscience. With an esteemed impact factor that reflects its significance in the academic community, this journal occupies an exceptional place in the 2023 Q1 category for neuroscience (miscellaneous) and boasts a leading Scopus rank of #1 out of 113 in general neuroscience, placing it within the top 1st percentile. Since its inception in 1998, NATURE NEUROSCIENCE has consistently delivered high-quality, peer-reviewed articles that contribute to our understanding of the nervous system, driving innovation and scholarship across disciplines. Although it does not offer open access, the journal remains a vital resource for researchers, professionals, and students seeking to stay at the forefront of neuroscientific discovery and discussion. Its editorial commitment to excellence ensures that it continually shapes the trajectory of neuroscience research well into 2024 and beyond, making it an indispensable asset for anyone passionate about the brain and its complexities.

FOLIA BIOLOGICA, published by Charles University Prague, First Faculty of Medicine, is an esteemed academic journal that has been contributing to the fields of Biochemistry, Cell Biology, Developmental Biology, Genetics, Immunology, and Molecular Biology since its inception in 1961. With an ISSN of 0015-5500, this journal serves as a vital platform for researchers and professionals to disseminate their findings and advance knowledge within these disciplines. Despite its current Category Quartiles ranking in the lower tiers (Q3 and Q4), FOLIA BIOLOGICA continues to provide valued insights and foster scholarly dialogue, particularly in its paralleled fields. The journal is headquartered in Prague, Czech Republic, and operates without Open Access options, which emphasizes its focus on curated, peer-reviewed content essential for academicians and students. By bridging theoretical and practical knowledge, FOLIA BIOLOGICA remains committed to enriching the scientific community and serving as a cornerstone for future research innovations.

ASN Neuro is an esteemed academic journal published by Frontiers Media SA, focusing on critical advancements in the fields of neurology and neuroscience. Since its inception in 2009, it has established itself as an Open Access platform dedicated to fostering the dissemination of knowledge and research findings that address the complexities of the nervous system. With an impressive impact factor and consistently ranking in the top quartiles of its categories—Q1 in Neurology (clinical) and Q2 in Neuroscience (miscellaneous)—ASN Neuro is recognized for its high-quality publications that cater to the evolving challenges in clinical neurology and general neuroscience. Currently, it ranks 68th out of 400 journals in Clinical Neurology and 28th out of 113 in General Neuroscience, affirming its reputable position within the academic community. Researchers, professionals, and students alike are encouraged to contribute to and benefit from this impactful journal as it presents a unique opportunity to engage with cutting-edge research, innovative methodologies, and insightful reviews in the ever-evolving landscape of brain science.

NEUROCHEMISTRY INTERNATIONAL, published by Pergamon-Elsevier Science Ltd, offers a premier platform for researchers and professionals in the realms of cell biology and cellular and molecular neuroscience. Established in 1980 and continuing its passion for advancing the field, this esteemed journal enhances scientific collaboration with a notable 2023 Q2 ranking in both relevant categories, placing it among the top-tier publications in its discipline with a Scopus rank of 23/97 for Cellular and Molecular Neuroscience. With its focus on groundbreaking research, the journal provides a wealth of vital data and insights that drive forward our understanding of neurochemistry and its implications in health and disease. While not an Open Access journal, NEUROCHEMISTRY INTERNATIONAL is integral for professionals, academics, and students aiming to stay at the forefront of neurobiological research innovations, making significant contributions to both academia and clinical applications.

eNeuro is a prominent open-access journal published by the Society for Neuroscience, dedicated to advancing the field of neuroscience through the dissemination of high-quality research. Launched in 2015, it reflects its commitment to accessibility by providing a platform for innovative studies and advancements in neurobiology. The journal holds a strong reputation, achieving a Q1 ranking in Medicine (miscellaneous) and a Q2 in Neuroscience (miscellaneous) as of 2023, with Scopus rankings placing it at #56 out of 113 in General Neuroscience, marking it in the 50th percentile. With its convergence to cover articles from 2014 to 2024, eNeuro continues to serve as a vital resource for researchers, professionals, and students alike, offering a comprehensive hub for the latest discoveries and theoretical developments in neuroscience. As part of its mission, eNeuro aims to foster collaboration and inspire the academic community with openly accessible content, making significant contributions to scientific discourse.

Translational Neurodegeneration, an esteemed journal in the field of neuroscience, is published by BMC and has been an open access platform since 2012, delivering high-quality research from its base in the United Kingdom. With an impressive impact factor reflecting its significant contributions, this journal focuses on critical advancements in cellular and molecular neuroscience, cognitive neuroscience, and clinical neurology, boasting a Q1 ranking across all these categories as of 2023. Researchers and professionals benefit from its extensive reach, characterized by exceptional Scopus rankings that place it in the top percentile of its field. The journal serves as a vital resource for academics and healthcare practitioners alike, aiming to bridge the gap between laboratory discoveries and clinical applications, thereby enhancing understanding and treatment of neurodegenerative diseases. With its commitment to open access, Translational Neurodegeneration ensures that its published research is accessible to a global audience, promoting collaboration and knowledge exchange within the scientific community.

PROGRESS IN NEUROBIOLOGY is a prestigious journal dedicated to advancing the field of neuroscience, published by Pergamon-Elsevier Science Ltd. With an impressive impact factor, it stands as a critical resource for researchers, professionals, and students alike, featuring rigorous peer-reviewed articles that explore the latest developments in neurobiology. The journal has established itself as a leading publication, ranked in the Q1 category for Neuroscience (miscellaneous) and holding a notable 13/113 rank in General Neuroscience per Scopus metrics, placing it in the top 12% of its field. Since its inception in 1959, PROGRESS IN NEUROBIOLOGY has covered a wide array of topics, from molecular mechanisms to cognitive processes, fostering a comprehensive understanding of brain functions. While the journal is not open access, it ensures accessibility to profound knowledge through institutional subscriptions. Researchers and scholars will find critical analyses and innovative research that are pivotal for both foundational knowledge and cutting-edge investigations in the neuroscience realm.

METABOLIC BRAIN DISEASE, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal dedicated to advancing our understanding of the metabolic processes impacting brain health and disease. Established in 1986 and set to continue until 2024, this journal encompasses a wide range of interdisciplinary research that intersects the fields of Biochemistry, Cellular and Molecular Neuroscience, and Neurology, as evidenced by its notable quartile placements in Q2 and Q3 for 2023. With an ISSN of 0885-7490 and an E-ISSN of 1573-7365, it serves as a vital resource for researchers and practitioners aiming to deepen their insights into cerebral metabolic disorders and their implications. Although currently not an Open Access option, its rigorous peer-review process ensures that high-quality, impactful research reaches its audience. Showcasing a significant rank within the top percentile of its categories, METABOLIC BRAIN DISEASE is instrumental in shaping the future of neurological research and clinical applications.